Company intelligence / Profile preview

Wayshine Biopharm

Shanghai, Shanghai, Chinawayshinebiopharm.com ↗

Ownership: Private
Development stage: Phase 2

Overview

WSD-0922, their lead candidate, is currently in Phase 2 clinical trials for non-small cell lung cancer. It previously received IND approval from FDA with Phase 1 clinical trials conducted at Mayo Clinic. WSD-0628 has received IND approval for glioma treatment. WSD-1227 is in preclinical development for brain metastases.

Therapeutic areas: Oncology
Modalities: Small molecule drugsBiological products
Industry: Biotech

Drug pipeline

8 assets

WSD-0922

7 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Wayshine Biopharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wayshine Biopharm.

Explore the full profile